Phase 1 Results Of Moderna Coronavirus Vaccine Are Positive

( The early results on Moderna’s coronavirus vaccine are all positive.
The company announced Monday that the vaccine produced antibodies for COVID-19 in all 45 human participants of their study.
The study broke the participants into groups of 15 people, giving them either doses of 25 micrograms, 100 mcg or 250 mcg. They all received two doses via intramuscular injection in the upper arm, roughly 28 days apart from one another.
Approximately two weeks following that second dose, at day 43, the levels of antibodies seen in the 25 mcg group were at similar levels to those seen in blood samples from people who have actually recovered from COVID-19. And those who receive 100 mcg had antibodies that “significantly exceeded levels” as those in patients who have recovered.
Data for the 250 mcg group were not available, Moderna officials said.
In at least eight study participants, the vaccine also produced neutralizing antibodies to fight COVID-19. What’s more, the company said the levels of these were either the same or higher than those seen in blood samples of people who have recovered from COVID-19.
Many medical experts say these neutralizing antibodies are essential in acquiring future protection from the virus.
In a statement, Modern’s chief medical officer Tal Zaks said:
“These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 [micrograms]. When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials.”
Moderna’s vaccine uses messenger RNA, also known as mRNA, as genetic material that was produced in their lab. It’s basically code for the body that tells it what cells to build. In the case of this vaccine, the mRNA is telling the body to produce an antigen that could induce an immune response to coronavirus.
According to the company, phase one of the trials showed the vaccine was generally safe, and participants tolerated it well. Adverse events were most notable in the 250 mcg group, where three participants developed “grade 3 systemic symptoms.”
While these are just findings from phase one of Moderna’s human trials, they are positive results for sure. Phase two of their trials will include about 600 participants. If all goes well, the company said it will begin phase three sometime in July.
Modern is the first company to release any results of a vaccine for coronavirus. There are more than 100 vaccines under development across the world, according to the World Health Organization. At least eight of these are in the human trials phase.
Moderna is working with the Department of Health and Human Services’ National Institutes of Health to fast-track the development of a coronavirus vaccine.
Phase one included testing the vaccine on 45 males and non-pregnant females who were between 18 and 55 years old.